{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:07:41Z","timestamp":1773338861096,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21nf0101624"],"award-info":[{"award-number":["JP21nf0101624"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.035","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T17:03:36Z","timestamp":1651251816000},"page":"3380-3388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I\/II randomized controlled trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Taisei","family":"Masuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenkichi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sakui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron P","family":"Schuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.04.035_b0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.04.035_b0010","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.035_b0015","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.035_b0020","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.035_b0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.035_b0030","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Principles for the evaluation of vaccines against the novel coronavirus SARS-CoV-2. Version: 02 September 2020. https:\/\/www.pmda.go.jp\/files\/000237021.pdf. Accessed August 2021."},{"key":"10.1016\/j.vaccine.2022.04.035_b0035","unstructured":"U.S. Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials, September 2007. https:\/\/www.fda.gov\/media\/73679\/download. Accessed September 2021."},{"key":"10.1016\/j.vaccine.2022.04.035_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003769","article-title":"Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial","volume":"18","author":"Formica","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2022.04.035_b0045","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.04.035_b0050","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1038\/s41467-021-27316-2","article-title":"A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults","volume":"12","author":"Haranaka","year":"2021","journal-title":"Nat Commun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:25Z","timestamp":1759403665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22004637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":10,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22004637"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I\/II randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}